Xgeva Dosage/Direction for Use

Important Administration Instructions: Denosumab (XGEVA) is intended for subcutaneous route only and should not be administered intravenously, intramuscularly, or intradermally.
Multiple Myeloma and Bone Metastasis from Solid Tumors: The recommended dose of denosumab (XGEVA) is 120 mg administered as a subcutaneous injection every 4 weeks in the upper arm, upper thigh, or abdomen.
Administer calcium and vitamin D as necessary to treat or prevent hypocalcemia [see Hypocalcemia under Precautions].
Giant Cell Tumor of Bone: The recommended dose of denosumab (XGEVA) is 120 mg administered every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy. Administer subcutaneously in the upper arm, upper thigh, or abdomen.
Administer calcium and vitamin D as necessary to treat or prevent hypocalcemia [see Hypocalcemia under Precautions].
Hypercalcemia of Malignancy: The recommended dose of denosumab (XGEVA) is 120 mg administered every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy. Administer subcutaneously in the upper arm, upper thigh, or abdomen.
Preparation and Administration: Visually inspect denosumab (XGEVA) for particulate matter and discoloration prior to administration. Denosumab (XGEVA) is a clear, colorless to pale yellow solution that may contain trace amounts of translucent to white proteinaceous particles. Do not use if the solution is discolored or cloudy or if the solution contains many particles or foreign particulate matter.
Prior to administration, denosumab (XGEVA) may be removed from the refrigerator and brought to room temperature (up to 25°C) by standing in the original container. This generally takes 15 to 30 minutes. Do not warm denosumab (XGEVA) in any other way.
Use a 27-gauge needle to withdraw and inject the entire contents of the vial. Do not re-enter the vial. Discard vial after single-dose or entry.